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Abstract
Trial Design
Previous studies suggested that poxvirus-based vaccines might be instrumental in the ther-
apeutic HIV field. A phase I clinical trial was conducted in HIV-1-infected patients on highly
active antiretroviral therapy (HAART), with CD4 T cell counts above 450 cells/mm3 and
undetectable viremia. Thirty participants were randomized (2:1) to receive either 3 intramus-
cular injections of MVA-B vaccine (coding for clade B HIV-1 Env, Gag, Pol and Nef anti-
gens) or placebo, followed by interruption of HAART.
Methods
The magnitude, breadth, quality and phenotype of the HIV-1-specific T cell response were
assayed by intracellular cytokine staining (ICS) in 22 volunteers pre- and post-vaccination.
Results
MVA-B vaccine induced newly detected HIV-1-specific CD4 T cell responses and expanded
pre-existing responses (mostly against Gag, Pol and Nef antigens) that were high in magni-
tude, broadly directed and showed an enhanced polyfunctionality with a T effector memory
(TEM) phenotype, while maintaining the magnitude and quality of the pre-existing HIV-1-
specific CD8 T cell responses. In addition, vaccination also triggered preferential CD8+ T
cell polyfunctional responses to the MVA vector antigens that increase in magnitude after
two and three booster doses.
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Conclusion
MVA-B vaccination represents a feasible strategy to improve T cell responses in individuals
with pre-existing HIV-1-specific immunity.
Trial Registration
ClinicalTrials.gov NCT01571466
Introduction
Highly active antiretroviral therapy (HAART) has dramatically improved the clinical outcome
in human immunodeficiency virus (HIV)-infected individuals through sustained suppression
of viral replication [1]. However, HAART alone is unable to clear HIV-1 infection, likely in
part due to the persistence of viral reservoirs [2–5]. Despite the benefits associated with
HAART use, long-term drug regimens fail for many patients due to drug resistance, non-
adherence or toxicity [6]. Therefore, there is an urgent need to develop therapeutic strategies
that can eliminate persistent viral reservoirs and boost host immunity to control HIV-1 viral
replication upon discontinuation of HAART. Therapeutic HIV-1 vaccination is one approach
that could potentially achieve these goals through the stimulation of effective HIV-1-specific T
cell responses; primarily cytolytic/virus suppressive CD8 T cells with supporting CD4 T help
[7–11].
Attenuated poxviruses such as canarypox, fowlpox, NYVAC and Modified Vaccinia Virus
Ankara (MVA) have been applied in several therapeutic HIV-1 vaccination trials with encour-
aging results in terms of activation of HIV-1-specific T cell responses, but the outcomes of viral
load reduction after HAART interruption have been quite discrepant (for review [11]).
We have previously shown that anMVA vector expressing the HIV-1 Env, Gag, Pol and Nef
antigens from clade B (termedMVA-B) was safe and broadly immunogenic when tested in a
phase I clinical trial in human healthy volunteers, inducing broad, polyfunctional and long-lasting
HIV-1-specific CD4 and CD8 T cell responses, as well as humoral responses against Env in most
of the vaccinees [12, 13]. Moreover, vector replication and expression of HIV-1 antigens by
MVA-B were not affected when HIV-1 protease inhibitors were used during in vitro infection [14].
We have recently described a therapeutic HIV-1 vaccination phase I clinical trial (termed
RISVAC03), consisting of 3 doses of MVA-B vaccination, and reported to be safe, well toler-
ated and with the result of increasing Gag-specific T cell responses when analyzed by ELISPOT
assay. A delay in viral rebound in patients was observed but was not associated with immuno-
genicity and vaccination did not have an impact in viral reservoir even when the vaccine was
given in combination with disulfiram [15]. To extend these findings, here we have evaluated by
intracellular cytokine staining (ICS) the magnitude, breadth, polyfunctionality and phenotypic
profile of the HIV-1-specific CD4 and CD8 T cellular immune responses elicited in chronically
HIV-1-infected subjects on HAART, before and after MVA-B administration. We have also
assessed the ability of this therapeutic approach to induce MVA vector-specific T cell responses
following booster doses of the vaccine. Our findings showed the CD4 and CD8 T cell immuno-
logical impact of MVA-B vaccination in HIV-1-infected individuals on HAART.
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Materials and Methods
Ethics Statement
The RISVAC03 study was approved by the Hospital Clinic (Barcelona), Hospital Germans
Trias i Pujol (Badalona) and Hospital Gregorio Marañón (Madrid) ethical review boards
(Authorized: June 2, 2011) and by the Spanish Regulatory Authorities (Clinical Trials.gov iden-
tifier: NCT01571466; Registered: November 9, 2011). The study was explained to all patients in
detail and all participants signed written informed consent documents. The authors confirm
that all ongoing and related trials for this study are registered. The protocol of the RISVAC03
clinical trial is detailed in S1 Protocol and the checklist with specific information related with
this study can be consulted in S1 CONSORT Checklist.
Study design
A total of 30 chronic HIV-1-infected patients on HAART with CD4 T cell counts above 450
cells/mm3 and undetectable viremia (<50 copies/ml) were enrolled in a phase I, double-blind,
placebo-controlled trial conducted at three HIV-1 units in Barcelona (Hospital Clinic), Bada-
lona (Hospital Germans Trias i Pujol) and Madrid (Hospital Gregorio Marañón), Spain,
between November 2011 and December 2013. The random allocation and blinding of volun-
teers were defined at each clinical center and the clinical characteristics of the patients have
been previously described [15]. One of the volunteers withdrew his consent to the study. For
the phase I therapeutic clinical trial, the volunteers were randomly allocated to receive three 0.5
ml injections of MVA-B (108 PFU/dose) (n = 20) or placebo (n = 10) by intramuscular route at
weeks 0, 4 and 16. HAART was interrupted 8 weeks after the last dose of MVA-B (week 24).
The safety profile, immunogenicity evaluated by ELISPOT and HIV-1 plasma viral load (pVL)
rebound after HAART interruption of the RISVAC03 clinical trial have been recently described
[15]. Cryopreserved peripheral blood mononuclear cells (PBMCs) were provided by the Span-
ish HIV HGM BioBank (RED RIS). Blood samples were processed following current proce-
dures and frozen immediately after reception [16]. For the present study, sufficient cell
material was available to assess the antigen-specific T cell immune responses in 22 HIV-
1-infected patients (14 vaccinees and 8 placebos). Note that the dropout reasons (withdrawal
of consent or lack of sufficient biological material for the analysis) are unrelated to the treat-
ment, so that the losses can be considered to be random and no bias is expected by the lack of
these samples. PBMCs were analyzed by polychromatic ICS assay from pre- (week 0) and post-
vaccination (weeks 6, 18 and 24) samples. The duration of participant follow-up was 48 weeks
(Fig 1). A table showing baseline demographic and clinical characteristics of each group has
been previously reported [15].
MVA-B vaccine
MVA-B vector was derived from the attenuated MVA poxvirus strain and its generation has
previously been described [17]. It expresses simultaneously and under the same synthetic
early/late viral promoter the genes encoding for monomeric gp120 from the HIV-1 primary
isolate BX08 as a cell-released product and Gag-Pol-Nef (GPN) from HIV-1 clone IIIB as an
intracellular polyprotein of 160 kDa. MVA-B was genetically stable, even when grown and
purified at a large scale under good manufacturing practices (GMP) as previously described
[17].
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Fig 1. Flow chart of the RISVAC03 study design and distribution of volunteers. (A) A total of 31 volunteers were randomized (21 to the MVA-B arm and
10 to the placebo arm) but one was excluded. One volunteer withdrew consent and 29 volunteers received three doses of the vaccine or placebo. Seven
patients had suboptimal sample availability so the immunogenicity to vaccination or placebo was assessed by ICS in 22 volunteers. All 29 participants were
included in the safety analysis. V: vaccine; P: placebo. (B) Chronological diagram showing the vaccination schedule, the HAART interruption timeline, the
immunogenicity endpoints and the determination of HIV-1 viral loads.
doi:10.1371/journal.pone.0141456.g001
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HIV-1 peptides
All HIV-1 peptides used were>80% purity and provided by EuroVacc Foundation. Overlap-
ping peptides (15-mers with 11 amino acids overlapping, n = 450) spanning the entire HIV-1
Env, Gag, Pol and Nef regions from clade B included in the MVA-B vector were grouped in
eight pools and the amino acid position and number of peptides per pool have been previously
described [13]. For immunological analyses they were clustered as follows: Env pool (Env-1
and Env-2), Gag pool (Gag-1 and Gag-2) and GPN pool (GPN-1, GPN-2, GPN-3 and GPN-4).
The Gag-derived peptides included in the Gag pool are not repeated in the GPN pool.
Flow cytometric assays
Cryopreserved PBMCs were thawed and rested overnight in RPMI 1640 medium containing
10% FBS. After resting, PBMCs were stimulated during 6 h in complete RPMI 1640 medium
containing 1 μl/ml GolgiPlug (BD Biosciences), 2 μMmonensin (eBioscience), anti-CD107a-
FITC (BD Biosciences) and 1 ug/ml each of the different HIV-1 peptide pools. For the detec-
tion of anti-vaccinia response, PBMCs were stimulated as described above but using as stimu-
lus autologous PBMCs infected with MVA at 2 PFU/cell in a ratio of 2:1. At the end of the
stimulation period, cells were washed, stained for the surface markers, fixed and permeabilized
(Cytofix/Cytoperm Kit; BD Biosciences) and stained intracellularly using the appropriate fluo-
rochromes. Dead cells were excluded using the violet LIVE/DEAD stain kit (Invitrogen). For
functional analyses, the following fluorochrome-conjugated antibodies were used: CD4-Alexa
700, CD8-APC-H7, IFN-γ-PerCP-Cy5.5, IL-2-APC and TNF-α-PE-Cy7. In addition, for phe-
notypic analyses, the following antibodies were used: CCR7-PE and CD45RA-PE-CF594. All
antibodies were from BD Biosciences. Cells were acquired using a GALLIOS flow cytometer
(Beckman Coulter). Analyses of the data were performed using FlowJo software version 8.5.3
(Tree Star, Ashland, OR). The average number of total events acquired was about 3 x 105 cells.
After gating, boolean combinations of single functional gates were then created using FlowJo
software to determine the frequency of each response based on all possible combinations of
cytokines expression or all possible combinations of differentiation markers expression. Back-
ground responses detected in negative control tubes (non-stimulated PBMCs) were subtracted
from those detected in stimulated samples for every specific functional combination.
Data analysis and statistics
In order to compare the different immune responses to the different stimuli, we computed for
each patient and each time point the proportion, p1, of cells responding to the specific stimuli.
We, then, computed the probability distribution associated to this experimental measurement
as a Beta probability density function with Nresponding+1 and Ntotal-Nresponding+1 degrees of
freedom [18, 19] (being Nresponding the number of responding cells and Ntotal the total number
of cells). In our procedure, we estimate the a posteriori probability density function of the esti-
mated proportion. The confidence intervals of our estimates do not need to be symmetric and
they are not based on any assumption (other than the proportion is between 0 and 1). In those
comparisons in which two time points were involved (t0 and tF), we calculated for each individ-
ual the probability density function of the random variable Δp = pF-p0 (i.e., we explicitly con-
sidered the paired nature of samples) by calculating the integral implied by the subtraction
(note that the probability density distributions of pF and p0 are known thanks to a previously
published methodology [19]). Then, we used a Wilcoxon signed rank test to check whether
there was a difference between the p1 populations of two time points or two groups.
Analysis and presentation of distributions were performed using MATLAB 2013 and SPICE
version 5.1, downloaded from http://exon.niaid.nih.gov [20]. Comparison of distributions was
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performed using a Student's T test and a partial permutation test as described [20]. All values
used for analyzing proportionate representation of responses are background-subtracted.
Results
MVA-B vaccination significantly improves the frequency, magnitude and
breadth of HIV-1-specific CD4 T cell responses, while maintaining HIV-
1-specific CD8 T cell responses
Vaccine-induced T cell responses were assessed in 22 volunteers (14 vaccinees and 8 placebos)
by ICS assay after the stimulation of PBMCs with the different HIV-1 peptide pools (Env, Gag
and GPN). The HIV-1-specific CD4 T cell responses were based on the frequency of IFN-γ
and/or TNF-α and/or IL-2-producing cells, whereas the CD8 T cell responses were based on
the frequency of CD107a and/or IFN-γ and/or TNF-α and/or IL-2-producing cells. For each T
cell subset, the response was considered positive if the value in the stimulated sample was
3-fold the value obtained in the non-stimulated control and if the background-subtracted mag-
nitude was higher than 0.02%. The background for the different cytokines in the non-stimu-
lated controls never exceeded 0.015%.
As shown in Fig 2A in vaccinees, the analysis of the number of positive Env-, Gag- and
GPN-specific CD4 T cell responses revealed that MVA-B immunization significantly induced
newly detected HIV-1 antigen-specific CD4 T cell responses after two (W6, n = 19 total
responses, p = 0.002) or three (W18, n = 22, p = 0.0002) doses compared to baseline time point
(W0, n = 5). CD4 T cell responses generated persisted at the time of HAART interruption
(W24, n = 16, p = 0.01) relative to last vaccination. However, the number of positive Env-,
Gag- and GPN-specific CD8 T cell responses did not show any significant temporal variation
associated with the administration of the vaccine. On the other hand, HIV-1-specific CD4 and
CD8 T cell responses did not change over time in placebo group (Fig 2A). Increases in the mag-
nitude of the pre-existing HIV-1-specific CD4 and CD8 T cell responses were also detected
after MVA-B immunization in 64.3% and 50% of the vaccinees, respectively, although statisti-
cal significances were only achieved for CD4+ T cells (all p<0.05) (Fig 2B). Before vaccination,
the magnitude and frequency of HIV-1-specific CD4 T cell responses in placebo group were
significantly higher than in vaccinees (p = 0.032) but these responses were maintained
throughout all the time points analyzed, while in MVA-B recipients we observed the expansion
and appearance of newly detected HIV-specific CD4 T cell responses over time indicating that
re-exposure to the HIV antigens expressed by MVA-B vector has a benefit on the overall
immune responses (Fig 2B).
This increase of the overall HIV-1-specific CD4 T cell responses detected post-vaccination
in vaccinees was mostly due to an enhancement in the frequency and magnitude of the Gag-
and GPN-specific responses and to a lesser extent due to Env-specific responses (Fig 3A, upper
panels). In the case of the newly detected HIV-1-specific CD4 T cells, we could not distinguish
if they were derived from naïve CD4 T cells or from pre-existing HIV-1-experienced CD4 T
cell responses which were below the threshold level of detection. HIV-1-specific CD8 T cell
responses were detected in all of the 22 volunteers pre- and post-vaccination, with preference
in the order of Gag = GPN>Env. Although MVA-B vaccination induced an increase in the
magnitude of the Gag- and GPN-specific CD8 T cell responses, these differences were not sig-
nificant (Fig 3A, lower panels). In the placebo group, the HIV-1-specific CD4 and CD8 T cell
responses pre- and post-vaccination were mainly directed against Gag and GPN, with the Gag-
specific CD4 T cell responses before vaccination being significantly higher than the response
detected in subjects receiving the vaccine (p = 0.032) (Fig 3A). As shown in Fig 3B, in the vacci-
nated group most (67%) individuals showed pre-existing HIV-1-specific CD4 T cell responses
MVA-B as Therapeutic HIV Vaccine
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Fig 2. Overall HIV-1-specific T cell responses induced throughout the study. (A) Total HIV-1-specific (Env+Gag+GPN) CD4 and CD8 T cell responses
in vaccinated and placebo groups before vaccination (W0), after two (W6) or three (W18) MVA-B or placebo doses or at time of HAART interruption (W24). n
values represent the number of positive Env-, Gag- and GPN-specific T cell responses at each time point. p-values for significant differences in the proportion
of responses were determined using the χ2 test for the equality of proportions. (B) Magnitude of the total HIV-1-specific (Env+Gag+GPN) CD4 and CD8 T cell
responses in vaccinees and placebos pre- and post-vaccination. The boxes indicate the mean and interquartile range (IQR). p-values for significant
differences were determined using the Wilcoxon rank sum test with continuity correction and are represented. All data are background-subtracted.
doi:10.1371/journal.pone.0141456.g002
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Fig 3. Frequency and breadth of HIV-1-specific CD4 and CD8 T cell responses. (A) Frequency of CD4 and CD8 T cell responses against Env, Gag or
GPN peptide pools in vaccinated and placebo groups before vaccination (W0), after two (W6) or three (W18) MVA-B or placebo doses or at time of HAART
interruption (W24). The boxes indicate the mean and IQR. p-values for significant differences were determined using theWilcoxon rank sum test with
continuity correction and are represented. All data are background-subtracted. (B) Breadth of HIV-1-specific CD4 and CD8 T cell responses at the different
time points. Percentages of vaccinees and placebos that recognize 1, 2 or 3 HIV-1 peptide pools in both T cell subsets are shown.
doi:10.1371/journal.pone.0141456.g003
MVA-B as Therapeutic HIV Vaccine
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to a single peptide pool only, while after MVA-B immunization there was an increase in the
breadth, with more than 60% of the vaccinees reacting against 2 or 3 peptide pools (Fig 3B, left
panel). In contrast, the HIV-1-specific CD8 T cell responses were broad and evenly distributed
to 1, 2 or 3 HIV-1 peptide pools at all time points assayed (Fig 3B, right panel). In the placebo
group, the breadth of the CD4 and CD8 HIV-1-specific T cell responses remained unchanged
before and after vaccination (Fig 3B). In terms of total cytokine production, MVA-B vaccina-
tion induced a significant increase in the percentages of HIV-1-specific CD4 T cells secreting
IFN-γ or IL-2 (Fig 4A). This was also the case for CD8 T cells secreting IL-2 (Fig 4B), since the
secretion of the other cytokines or the surface mobilization of CD107a in CD8 T cells were not
significantly affected by the vaccine (Fig 4B).
Overall these data demonstrated that MVA-B vaccine significantly improved the magnitude
and breadth of the pre-existing HIV-1-specific CD4 T cell responses, while maintaining the
HIV-1-specific CD8 T cell responses.
MVA-B vaccination significantly improved the polyfunctionality and T
effector memory phenotype of pre-existing HIV-1-specific CD4 T cell
responses, while maintaining the strength of HIV-1-specific CD8 T cell
responses
The functional and phenotypic profiles of HIV-1-specific CD4 and CD8 T cell responses were
analyzed pre- and post-vaccination by polychromatic ICS assay. For functional analyses, we
quantified the intracellular production of IFN-γ, IL-2 and TNF-α by HIV-1 Env-, Gag- and
GPN-specific CD4 T cells and additionally evaluated the surface mobilization of CD107a by
MVA-B immunogen-specific CD8 T cells. Pre-existing HIV-1-specific T cell responses were
highly polyfunctional in both vaccinee and placebo groups, with more than 40% of the CD4 T
cells and 60% of the CD8 T cells in the vaccinee group exhibiting at least two effector functions
(Figs 5 and 6). Still, MVA-B immunization improved the functional profile of the HIV-1-spe-
cific CD4 T cells by further increasing the frequencies of T cells secreting simultaneously IFN-γ
+IL-2+TNF-α (Fig 5A). Furthermore, MVA-B vaccination induced an increase in the frequen-
cies of HIV-1-specific CD8 T cells secreting simultaneously CD107a+IFN-γ+TNF-α (Fig 6A).
In the placebo arm, the functional profile of the HIV-1-specific CD4 and CD8 T cells was the
same at pre- and post-vaccination times (Figs 5B and 6B).
We also characterized the differentiation stages of the responding HIV-1-specific CD4 and
CD8 T cells into T central memory (TCM: CD45RA- CCR7+), T effector memory (TEM:
CD45RA- CCR7-) or terminally differentiated T effector memory (TEMRA: CD45RA+ CCR7-)
populations as previously described [21]. HIV-1-specific CD4 T cell responses were mostly of
TEM phenotype prior to immunization in both vaccinees and placebos and the percentage of
CD4+ T cells with TEM phenotype in placebo group was significantly higher than in vaccines
(p = 0.022) but only in MVA-B recipients the proportion of this population significantly
enhanced (about 3-fold) over time (Fig 7A). Furthermore, the pre-existing HIV-1-specific CD8
T cell responses were mostly of TEM phenotype and to a lesser extent of TEMRA phenotype in
both the vaccinee and placebo arms but were unchanged post-vaccination (Fig 7B).
MVA-B vaccination induced anti-vector specific T cell responses
We next wanted to define to what extent vaccinees responded to the antigens brought by the
MVA vector along different boosters. Anti-vector specific T cell responses were assessed by
ICS assay after the stimulation of isolated PBMCs with autologous cells infected with vaccinia
virus (VACV) strain MVA. This approach gives higher and more functional T cells than stimu-
lation with peptide-pulsed PBMCs. None of the placebo recipients had positive T cell responses
MVA-B as Therapeutic HIV Vaccine
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Fig 4. Percentages of HIV-1-specific CD4 and CD8 T cells secreting cytokines or mobilizing CD107a. Frequency of HIV-1-specific CD4 (A) and CD8
(B) T cells producing IFN-γ, TNF-α, IL-2 or mobilizing CD107a. The box plots show the distribution of responses in vaccinees and placebos before
vaccination (W0), after two (W6) or three (W18) MVA-B or placebo doses or at time of HAART interruption (W24). The boxes indicate the mean and IQR.
Data points represent the sum of the frequencies obtained against Env, Gag and GPN peptide pools. p-values were determined using the Wilcoxon rank sum
test with continuity correction and are represented. Asterisk indicates that significant differences between vaccinated and placebo groups were observed at
this time point. All data are background-subtracted.
doi:10.1371/journal.pone.0141456.g004
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Fig 5. Functional profile of HIV-1-specific CD4 T cells. Frequencies of HIV-1-specific CD4 T cells (directed against Env+Gag+GPN) that express IFN-γ
and/or IL-2 and/or TNF-α in vaccinated (A) or placebo (B) groups before vaccination (W0), after two (W6) or three (W18) MVA-B or placebo doses or at time
of HAART interruption (W24). All the combinations of the different functions contributing to the overall HIV-1-specific responses are shown on the x axis,
whereas the percentages of the functionally distinct cell populations within cytokine-producing CD4+ T cells are shown on the y axis. Responses are grouped
and color-coded on the basis of the number of functions. The boxes correspond to the individual data points and IQR at the different time points. The pie
MVA-B as Therapeutic HIV Vaccine
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against the vector pre- and post-vaccination. In the vaccine group, no anti-VACV CD8 T cell
responses were detected at pre-vaccination time point (W0) but were significantly boosted
after 2 or 3 doses of MVA-B vaccine (Fig 8A), with anti-vector specific T cell responses
detected in 12 out of 14 (86%) vaccinees. These vaccine-induced anti-vector responses were
highly polyfunctional, with about 70% of MVA-specific CD8 T cells displaying more than one
function (Fig 8B) and of TEM or TEMRA phenotype (Fig 8C). There was no correlation
between the vector specific immunity and the magnitude or breadth of the HIV-1-specific T
cell responses.
These findings showed that HIV-infected individuals under HAART treatment responded
to the MVA-B vaccine, by triggering specific polyfunctional CD8+ T cell responses to the vector
that were enhanced after two and three vaccine boosters. This vector-specific immunity does
not interfere with the magnitude or breadth of the HIV-1-specific T cell responses elicited,
highlighting the advantage of using poxvirus-based vectors as vaccine candidates.
Discussion
The desired clinical outcome of a therapeutic HIV-1 vaccine is to keep the viral load under con-
trol and restore CD4 T cell counts through CD8 T cell-mediated suppression of viral replica-
tion. Many different approaches have been assayed to achieve these results. They included
non-antigen specific (e.g. using cytokines such as IL-2, IL-12, IFN-γ, IL-7, IL-15, IL-21 or
blocking negative regulatory receptors such as PD-1 or CTLA-4) and HIV-1 antigen-specific
immune therapies using diverse platforms such as DNA vectors, viral vectors or dendritic cell-
based therapeutic vaccines [7–11]. More recently, immunotherapy based on broadly neutraliz-
ing antibodies has been shown to reduce viremia in HIV-infected individuals, offering a new
modality for HIV prevention, therapy and cure [22]. However, none of the therapeutic studies
have been able to control HIV infection for long periods of time, indicating that combined
approaches with vaccines and/or antivirals could be a strategy to enhance protective efficacy.
In this study we have evaluated the T cell immunological profile of a poxvirus-based vaccine
expressing the HIV-1 Env, Gag, Pol and Nef antigens from clade B (MVA-B) in HIV-
1-infected individuals on HAART, through detailed ICS analysis of CD4 and CD8 T cell
responses to both HIV-1 and MVA vector antigens. We have recently reported that this thera-
peutic HIV-1 vaccination protocol was safe and well tolerated and increased Gag-specific T cell
responses, when analyzed by ELISPOT assay [15]. Furthermore, we have previously demon-
strated that the MVA-B vaccine was safe and broadly immunogenic when tested in a phase I
clinical trial in human healthy volunteers [12, 13].
ICS analysis of the HIV-1-specific T cell immune responses elicited by MVA-B vaccination
in HIV-1-infected patients on HAART revealed the expansion and also the appearance of
newly detected HIV-1-specific CD4 T cell responses, mostly against Gag and GPN HIV-1 anti-
gens, that were high in magnitude, broad, polyfunctional and of TEM phenotype. Moreover,
MVA-B also improved, but not significantly (p>0.05), the magnitude of pre-existing HIV-
1-specific CD8 T cell responses preserving their antigen-specificity, frequency, breadth, poly-
functionality and phenotypic profile.
The immunological profile of the immune responses induced by MVA-B vaccination
observed in this investigation was associated with functional characteristics of T cell responses
that have been linked with an effective control of HIV-1 virus replication and with protection
against disease progression such as: preferential targeting of Gag epitopes (Fig 3A),
charts show the average proportion of the HIV-1-specific CD4 T cell responses according to the functions. Comparison of distributions was performed using a
Student's T test and a partial permutation test as described [20]. All data are background-subtracted.
doi:10.1371/journal.pone.0141456.g005
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Fig 6. Functional profile of HIV-1-specific CD8 T cells. Frequencies of HIV-1-specific CD8 T cells (directed against Env+Gag+GPN) that mobilize CD107a
and/or express IFN-γ and/or IL-2 and/or TNF-α in vaccinated (A) or placebo (B) groups before vaccination (W0), after two (W6) or three (W18) MVA-B or
placebo doses or at time of HAART interruption (W24). All the combinations of the different functions contributing to the overall HIV-1-specific responses are
shown on the x axis, whereas the percentages of the functionally distinct cell populations within cytokine-producing CD8+ T cells are shown on the y axis.
Responses are grouped and color-coded on the basis of the number of functions. The boxes correspond to the individual data points and IQR at the different
time points. The pie charts show the average proportion of the HIV-1-specific CD8 T cell responses according to the functions. Comparison of distributions
was performed using a Student's T test and a partial permutation test as described [20]. All data are background-subtracted.
doi:10.1371/journal.pone.0141456.g006
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concomitant CD4+ and CD8+ T cell responses (Figs 2, 3 and 7), higher capacity to secrete mul-
tiple cytokines and chemokines (polyfunctionality) (Figs 4, 5 and 6), particularly IL-2, or
higher expression of lytic factors such as perforin, granzymes and CD107a expression (Fig 4)
[23–28]. The fact that the MVA-B vaccine stimulated CD4+ T cells with no adverse effects on
Fig 7. Phenotype of the HIV-1-specific CD4 and CD8 T cell responses. Frequencies of HIV-1-specific CD4 (A) and CD8 T cells (B) (directed against Env+
Gag+GPN) with phenotype T central memory (TCM: CD45RA- CCR7+), T effector memory (TEM: CD45RA- CCR7-) or terminally differentiated T effector
memory (TEMRA: CD45RA+ CCR7-), in vaccinees and placebos before vaccination (W0), after two (W6) or three (W18) MVA-B or placebo doses or at time
of HAART interruption (W24). The boxes correspond to the individual data points and IQR at the different time points. p-values for significant differences were
determined using the Wilcoxon rank sum test with continuity correction and are represented. All data are background-subtracted.
doi:10.1371/journal.pone.0141456.g007
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Fig 8. Anti-vector-induced T cell responses throughout the study. (A) Percentages of CD4 and CD8 T cell responses against MVA-infected cells at the
different time points in the vaccinee group. The boxes indicate the mean and interquartile range (IQR). p-values for significant differences were determined
using the Wilcoxon rank sum test with continuity correction and are represented. Asterisks indicate that significant differences between vaccinated and
placebo groups were observed at the different time points. All data are background-subtracted. (B) Frequencies of MVA-specific CD8 T cells that mobilize
CD107a and/or express IFN-γ and/or IL-2 and/or TNF-α in vaccinated subjects. All the combinations of the different functions contributing to the overall MVA-
MVA-B as Therapeutic HIV Vaccine
PLOS ONE | DOI:10.1371/journal.pone.0141456 November 6, 2015 15 / 20
the patients was an added advantage, as CD4 T cells are the targets of HIV infection and main-
tenance of these cells favors a better health status of the patients. The role of CD4+ T cells in
maintaining HIV-specific cellular and humoral responses has long been supported by previous
and recent studies, highlighting the potential therapeutic benefits this could have in relation to
either HIV remission or eradication [29, 30]. Hence, the boost in HIV-specific CD4 T cell
responses that we have observed in our therapeutic phase I clinical trial with MVA-B may con-
tribute to reduce HIV viral load and help on its eradication.
Previously, different MVA-based therapeutic candidates have been evaluated in HIV-
1-infected subjects on HAART [31]. They expressed different HIV-1 antigens such as Nef [32,
33], clade A p24/17 and multiple CD8 T cell epitopes [34–36], Gag [37] or multiple antigens
(Env, Tat, Rev, Nef and RT) [38]. These candidates were shown to be immunogenic to different
extents, inducing both CD4 and CD8 antigen-specific T cell responses with a polyfunctional
profile. However, these past studies did not evaluate how the improvements in the immune
responses correlated with virological control after treatment interruption. In addition, a
NYVAC-based vaccine candidate (termed NYVAC-B) expressing the same HIV-1 antigens as
our MVA-B candidate, induced broad and polyfunctional HIV-1-specific T cell responses;
however, the antiviral effects after vaccination were not evaluated either [39]. Similarly to
MVA-B, NYVAC-B induced in HIV-1-infected patients on HAART the appearance of newly
detected HIV-1-specific CD4 T cell responses and an increase in Gag-specific T cell responses
[39]. Previous studies have also assayed the potential of poxvirus-derived candidates based on
ALVAC or fowlpox strains [40–43]. In most of them, the efficacy in HIV-1 viral control was
determined after discontinuation of HAART but only in those protocols that combined the
vaccine with cytokines such as IL-2 or IFN-γ a partial prevention of viral rebound was
observed. The protection was correlated with the presence of HIV-1-specific CD4 T cell
responses [40, 41], IgG2 antibodies to HIV p24 [42, 43] and anti-V1/V2 antibodies [42].
In the RISVAC03 study we have previously observed that MVA-B vaccination induced a
modest delay in viral rebound after HAART interruption in a subset of vaccinees [15].
Although plasma viral load (pVL) rebounded in all patients, within a subset of vaccinees we
could distinguish between subjects with different dynamics of pVL rebound considering the
mean value of pVL at different times after HAART interruption or the time at which they
reached 50% of pre-HAART pVLs as indicators of virus control. This delay might be related
with the increased polyfunctional CD4+ T cell response and TEM phenotype observed in our
analysis. Due to the limited availability of PBMCs we could not perform a complete correlation
study in order to assess how CD4 and CD8 T cell immunity affected viral rebound. However,
we conducted a sub-study of HIV-1 viral rebound dynamics in 9 subjects (6 vaccinees and 3
placebos) during the first 12 weeks after HAART interruption. Although no correlation was
obtained due to the low number of individuals, we observed that at the time when HAART was
interrupted (W24) the vaccinees with a dynamic of delayed pVL rebound have higher frequen-
cies of Gag-specific CD8 T cells, higher percentages of HIV-1-specific CD4 T cells with TCM
phenotype and higher titers of anti-V1/V2 gp120 binding antibodies. However, these immune
specific responses are shown on the x axis, whereas the percentages of the functionally distinct cell populations within cytokine-producing CD8+ T cells are
shown on the y axis. Responses are grouped and color-coded on the basis of the number of functions. The pie charts show the average proportion of the
MVA-specific CD8 T cell responses according to the functions. Comparison of distributions was performed using a Student's T test and a partial permutation
test as described [20]. All data are background-subtracted. (C) Frequencies of MVA-specific CD8 T cells with phenotype central memory (TCM: CD45RA-
CCR7+), T effector memory (TEM: CD45RA- CCR7-) or terminally differentiated T effector memory (TEMRA: CD45RA+ CCR7-) in vaccinated subjects. The
boxes correspond to the individual data points and IQR at the different time points. p-values for significant differences were determined using theWilcoxon
rank sum test with continuity correction and are represented. Asterisks indicate that significant differences between vaccinated and placebo groups were
observed at the different time points. All data are background-subtracted.
doi:10.1371/journal.pone.0141456.g008
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parameters were not sufficient to provide HIV-1 viral control in the vaccinees. Hence, it seems
rather necessary to improve other immunological features which have been previously defined
to be associated with a better virus control and prevention of disease progression [26, 28, 44].
These improvements could be done by heterologous prime/boost protocols [45] in combina-
tion with reactivating strategies using potent substances that could promote the eradication of
HIV-1 in latently infected cells (for review [46]). Alternatively, the combined effects of MVA-B
vaccine enhancing T cell responses, together with infusion of broadly neutralizing antibodies
might favor a more effective control of HIV infection. Undoubtedly, therapeutic clinical trials
are needed to provide detailed information on immune parameters associated with virus
control.
In conclusion, our study demonstrates that MVA-B is a broadly immunogenic HIV/AIDS
vaccine candidate that stimulated polyfunctional HIV-specific CD4 T cell responses with a T
effector memory (TEM) phenotype in HIV-1-infected patients on HAART, and also enhances
vector-specific CD8 T cell responses. Thus, HIV-1 immunotherapy using MVA-B in combina-
tion with other strategies is a viable option to be explored in future clinical trials.
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